AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9008458
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg
Trial: 20224056
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose alteplase (0.90 ± 0.02 mg/kg)
Trial: 20224056
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose alteplase (0.72 ± 0.07 mg/kg)
Trial: 20224056
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose alteplase (0.90 ± 0.02 mg/kg) in patients ≥ 70 years old
Trial: 20224056
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose alteplase (0.72 ± 0.07 mg/kg) in patients ≥ 70 years old
Trial: 18359865
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg to 1,200 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Trial: 18359865
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (1,000 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Trial: 9777766
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus mid-potency corticosteroid cream
Trial: 9777766
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus high-potency corticosteroid cream
Trial: 9777766
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus placebo cream
Trial: 7835452
Drug: Diclofenac and
RxNorm normalized name: diclofenac and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac and gentamicin combination
Trial: 7835452
Drug: Betamethasone and
RxNorm normalized name: betamethasone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone and neomycin combination
Trial: 30904939
Drug: Metformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (up to 1 g twice daily)
Trial: 29693650
Drug: Phenylbutyrate (NaPB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutyrate (NaPB; 7.15 g•m‐2BSA•day‐1)
Trial: 29693650
Drug: Benzoate (NaBz;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoate (NaBz; 5.5 g•m‐2BSA•day‐1)
Trial: 29693650
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (MIX arm; 3.575 g NaPB and 2.75 g NaBz•m‐2BSA•day‐1)
Trial: 29693650
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (MIX arm)
Trial: 27620995
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin 40 mg once daily for 3-7 days before surgery
Trial: 27620995
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin 40 mg
Trial: 25080284
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of levodopa intake and subthalamic nucleus stimulation
Trial: 22574592
Drug: Biqi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biqi Capsule (BQC)
Trial: 19604584
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behaviour therapy (CBT) treatment program, 10 sessions over 20 weeks.
Trial: 15857738
Drug: Chemotherapy (FEM=5-FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FEM=5-FU, epirubicin, and mitomycin C)
Trial: 9392310
Drug: GST monitoring
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GST monitoring reported daily to the ward (reporting group)
Trial: 3109602
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose solution with 6 g salt
Trial: 3109602
Drug: Boiled macaroni
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled macaroni with 6 g salt
Trial: 3109602
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose solution without salt
Trial: 31506074
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) once daily for 20 minutes, electrical current increased up to 70 mA until contraction detected.
Trial: 26686043
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg to 300 mg daily)
Trial: 23485887
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein diet (VLPD; 0.3 g/kg bw/day)
Trial: 23485887
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD; 0.6 g/kg bw/day)
Trial: 21599433
Drug: Deferiprone 75
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week
Trial: 21599433
Drug: Deferiprone alone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone alone 75 mg/kg 7 days/week
Trial: 19439117
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (target group, blood glucose 6.2 to 8.3 mmol/L)
Trial: 19439117
Drug: Routine insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine insulin therapy (routine group, blood glucose 4.1 to 6.1 mmol/L)
Trial: 17012299
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day rosuvastatin therapy
Trial: 12455724
Drug: Antioxidant treatment
RxNorm normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant treatment
Trial: 29927398
Drug: Cytoflavin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (2 tablets 2 times a day)
Trial: 29927398
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (Control)
Trial: 25077847
Drug: Non-MBCT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MBCT group therapy
Trial: 22284022
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with varying levels of depressive symptoms (NO, SLOW, GO)
Trial: 22049891
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with ketamine 50 mg in drinking water 30 ml for 30 s, 5 min before induction of anaesthesia
Trial: 22049891
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with drinking water 30 ml
Trial: 15753530
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement of 25 mg daily for 14 days
Trial: 10569419
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg BID for 3-8 days preoperatively
Trial: 10569419
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg BID for 9-14 days preoperatively
Trial: 6349560
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group A and group C meningococcal polysaccharide vaccine
Trial: 30855463
Drug: Sufentanil 0.2
RxNorm normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.2 μg/kg
Trial: 31820593
Drug: Sufentanil 0.1
RxNorm normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.1 μg/kg
Trial: 30855463
Drug: Sufentanil 0.05
RxNorm normalized name: sufentanil 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.05 μg/kg
Trial: 30855463
Drug: Sufentanil 0
RxNorm normalized name: SUFentanil 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0 μg/kg (control group)
Trial: 30855463
Drug: Sufentanil 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.15 μg/kg
Trial: 24314857
Drug: Warm saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm saline mouth rinse six times daily (Group A)
Trial: 24314857
Drug: Warm saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm saline mouth rinse twice daily (Group B)
Trial: 19308417
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (treatment initiation)
Trial: 17279280
Drug: Nutritional guidance
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional guidance in the first year of life with monthly follow‐up home visits
Trial: 9852628
Drug: Germinated barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Germinated barley foodstuff (GBF) 30 g/day for 28 days
Trial: 2465457
Drug: Aprotinin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (700 mg approximately)
Trial: 27911869
Drug: TOF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOF regimen (paclitaxel 135 mg/m2 iv on day 1, oxaliplatin 100 mg/m2 iv on day 1, fluorouracil 500 mg/m2 continuous iv on day 1-5)
Trial: 27911869
Drug: SOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX regimen (oxaliplatin 130 mg/m2 iv on day 1, S-1 40 mg/60mg orally twice/day on days 1-14)
Trial: 21300736
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta‐1a (IFNβ‐1a) treatment
Trial: 16864757
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of recombinant human thyrotropin
Trial: 8791047
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neo‐adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks)
Trial: 1781051
Drug: Ibuprofen (Ibumetin)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (Ibumetin)
Trial: 1455326
Drug: Paracetamol/codeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/codeine combination (Citodon)
Trial: 28881347
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (500 mg capsules, 2 capsules daily for 12 weeks)
Trial: 28881347
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 placebo capsules daily for 12 weeks)
Trial: 26216378
Drug: Nebulized fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized fluticasone propionate (2000 mcg/day)
Trial: 16685542
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (1 mg/kg/day)
Trial: 16562650
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation therapy combined with chemotherapy
Trial: 12706932
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogen (CEE) (0.625 mg/day)
Trial: 12706932
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E(2)) (100 microg/day)
Trial: 10675209
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for TBM, duration not specified
Trial: 9586515
Drug: Michigan splint
RxNorm normalized name: influenza B virus B/Michigan/01/2021 antigen
DrugBank: Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (DB16917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Michigan splint therapy for two months
Trial: 23059922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no active treatment)
Trial: 8246258
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli O157 agglutinating antibodies
Trial: 8246258
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against whole intact E. coli O157 cells
Trial: 3542383
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for breast cancer
Trial: 27354079
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm with time-controlled, manualised wellness rehabilitation consultation focused on healthy nutrition and exercise post-chemotherapy.
Trial: 23468100
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of alcohol, clamped at a steady-state breath alcohol (BrAC) concentration of 60 mg/dL
Trial: 31928949
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline infusion
Trial: 16585985
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolevulinate photodynamic therapy (160 mg/g cream applied for 3 h prior to illumination by non‐coherent red light at 570‐670 nm, light dose 75 J/cm2)
Trial: 16585985
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolevulinate photodynamic therapy
Trial: 12669898
Drug: Daily ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ASA treatment after ASA desensitization
Trial: 1303336
Drug: Ivermectin 0.1
RxNorm normalized name: ivermectin 0.136 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.1 mg/kg orally at a single dose
Trial: 1303336
Drug: Ivermectin 0.2
RxNorm normalized name: ivermectin 0.272 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.2 mg/kg orally at a single dose
Trial: 1303336
Drug: Pyrantel pamoate
RxNorm normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel pamoate 10 mg/kg orally at a single dose
Trial: 3512031
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (heparin fragment) 5000 anti-factor Xa units once daily
Trial: 3512031
Drug: Conventional low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional low-dose heparin 5000 units twice daily
Trial: 16381629
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U weekly
Trial: 11502918
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 28 days, followed by 10 mg/day)
Trial: 3392552
Drug: r-metHuIFN-Con1 at
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHuIFN-Con1 at 30 mcg/m2/day
Trial: 3392552
Drug: r-metHuIFN-Con1 at
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHuIFN-Con1 at 45 mcg/m2/day
Trial: 29939055
Drug: Cumulative habituation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative habituation across treatment
Trial: 27289566
Drug: 30% decline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% decline in circulating tumor cell (CTC) count after treatment
Trial: 27289566
Drug: 30% CTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% CTC decline after treatment from an initial count ≥5 cells/7.5 ml
Trial: 22151005
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) hydrocortisone regimen (30 mg daily) for 2 weeks
Trial: 22151005
Drug: Low-dose (LD)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (LD) hydrocortisone regimen (17.5 mg daily) for 2 weeks
Trial: 19152905
Drug: Endoscopic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapies (including injection, thermocoagulation, clips)
Trial: 18813410
Drug: Injection alone
RxNorm normalized name: U-Tri-Lone Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection alone
Trial: 19152905
Drug: Injection followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection followed by thermal therapy
Trial: 17573581
Drug: Tolvaptan (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (doses not specified)
Trial: 17573581
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in serum sodium (1 mmol/l increase)
Trial: 8547730
Drug: Albuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2 inhalations 4 times daily)
Trial: 8547730
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 inhalations 4 times daily)
Trial: 375732
Drug: Cefazolin (Ancef),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (Ancef), administered intravenously in a high-dose, short perioperative regimen
Trial: 21529775
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus clarithromycin (CLM) 500 mg b.i.d. for 3 days
Trial: 19122034
Drug: FTY720 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 1.25 mg/day
Trial: 19122034
Drug: FTY720 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 5.0 mg/day
Trial: 19122034
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of FTY720 treatment
Trial: 19122034
Drug: FTY720 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 (both doses) after 24 months
Trial: 12370700
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain management diary with nurse coaching regarding the pain management program
Trial: 12370700
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain management diary for data collection
Trial: 7735515
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of a new, partially purified, characterized and standardized pollen extract of P. officinalis allergen (alum-absorbed depot preparation)
Trial: 2525985
Drug: Etodolac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (200 mg twice a day)
Trial: 2525985
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg once a day)
Trial: 2525985
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg three times a day)
Trial: 11291357
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg twice a day)
Trial: 31050763
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) + Care as Usual (CAU)
Trial: 21327911
Drug: Talniflumate (740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talniflumate (740 mg) with magnesium hydroxide (1 g)
Trial: 21327911
Drug: Talniflumate (740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talniflumate (740 mg) without magnesium hydroxide
Trial: 11973101
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 0.1%
Trial: 2486579
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine 12.5 mg
Trial: 2486579
Drug: Intravenous meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meperidine 25 mg
Trial: 29185604
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy (PT)